News
NONOF
40.69
NaN%
--
Novo Nordisk's CagriSema Launch in Focus -- Market Talk
Dow Jones · 1d ago
Novo Nordisk: Better Than It Looks, But Not A Buy Yet
Seeking Alpha · 1d ago
Novo Nordisk: Valuations Are Blind To The Upside
Seeking Alpha · 2d ago
Baron International Growth Fund Q3 2026 New Investments
Seeking Alpha · 4d ago
Eli Lilly's Weight-Loss Pill Shows Sleep Apnea Benefits. Can It Gain on Novo?
Barron‘s · 4d ago
Weekly Report: what happened at NONOF last week (1102-1106)?
Weekly Report · 4d ago
Novo Nordisk: Q3 Earnings Bust The Cannibalization Myth
Seeking Alpha · 5d ago
Why Hims & Hers Health Stock Was in Dire Need of This Eli Lilly Agreement
Barron‘s · 11/06 13:24
Novo Nordisk Owns The Oral Weight Loss Market At 7.8x Operating Income
Seeking Alpha · 11/06 11:16
Novo Nordisk: The Recovery Is Gaining Traction, Here's Why I'm Staying On Hold
Seeking Alpha · 11/05 11:14
Novo Nordisk Stock Shrugs Off Eli Lilly Threat as Weight-Loss Pill Shines in Earnings
Barron‘s · 11/04 15:02
Novo Nordisk Weight-Loss Pill Sales Soar. One Other Earnings Revelation Boosting the Stock.
Barron‘s · 11/04 13:30
Novo Nordisk Q3: Just The Report I Was Waiting For
Seeking Alpha · 11/04 13:19
*Novo Nordisk: Benefits of Weight-Loss Pill Outweigh Eating Restriction, CEO Says
Dow Jones · 11/04 13:19
*Novo Nordisk Weight-Loss Pill to Launch in Australia or Israel Next, CEO Says
Dow Jones · 11/04 13:19
*Novo Nordisk Weight-Loss Pill Benefiting From Change in Patient Perception, CEO Says
Dow Jones · 11/04 13:19
2 Reasons for Hope From Novo Nordisk Earnings
Barron‘s · 11/04 11:20
Pfizer CEO Bourla Bets the Viagra Playbook Can Crack the Obesity Market
Barron‘s · 11/04 10:30
Novo Nordisk beats top-line and bottom-line estimates; updates FY26 outlook
Seeking Alpha · 11/04 07:11
U.S. Futures Rally After Democrats Take Congress; AMD Pops After Earnings
Barchart · 11/04 05:45
More
Webull provides a variety of real-time NONOF stock news. You can receive the latest news about Novo-Nordisk A S through multiple platforms. This information may help you make smarter investment decisions.
About NONOF
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.